Prediction of survival by applying current prognostic models in diffuse large B-cell lymphoma treated with R-CHOP followed by autologous transplantation
Hong-Ghi LEE; Sung-Yong KIM; Inho KIM; Yeo-Kyeoung KIM; Jeong-A KIM; Yang-Soo KIM; Ho-Sup LEE; Jinny PARK; Seok-Jin KIM; Hyeok SHIM; Hyeon-Seok EOM; Byeong-Bae PARK; Junglim LEE; Sung-Kyu PARK; June-Won CHEONG; Keon-Woo PARK.
Blood Research
; : 160-166, 2015.
Artículo
en Inglés
| WPRIM | ID: wpr-36729
BACKGROUND:
Among the currently available prognostic models for diffuse large B-cell lymphoma (DLBCL), we investigated to determine which is most adoptable for DLBCL patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) followed by upfront autologous stem cell transplantation (auto-SCT).METHODS:
We retrospectively evaluated survival differences among risk groups based on the International Prognostic Index (IPI), the age-adjusted IPI (aaIPI), the revised IPI (R-IPI), and the National Comprehensive Cancer Network IPI (NCCN-IPI) at diagnosis in 63 CD20-positive DLBCL patients treated with R-CHOP followed by upfront auto-SCT.RESULTS:
At the time of auto-SCT, 74.6% and 25.4% of patients had achieved complete remission and partial remission after R-CHOP, respectively. As a whole, the 5-year overall (OS) and progression-free survival (PFS) rates were 78.8% and 74.2%, respectively. The 5-year OS and PFS rates according to the IPI, aaIPI, R-IPI, and NCCN-IPI did not significantly differ among the risk groups for each prognostic model (P-values for OS 0.255, 0.337, 0.881, and 0.803, respectively; P-values for PFS 0.177, 0.904, 0.295, and 0.609, respectively).CONCLUSION:
There was no ideal prognostic model among those currently available for CD20-positive DLBCL patients treated with R-CHOP followed by upfront auto-SCT.
Biblioteca responsable:
WPRO
Texto completo
Documentos relacionados